Compare Dover Corp (DOV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Zimmer Biomet Holdings Inc — how do they compare? Dover Corp trades at $207.92 (market cap $28.07B), while Zimmer Biomet Holdings Inc trades at $96.04 (market cap $18.55B). The key difference: Dover Corp is the larger of the two by market cap, and Dover Corp pays the higher dividend (1.01%). Which is the better fit depends on your goals.
| DOV | ZBH | |
|---|---|---|
Market Cap | $28.07B | $18.55B |
Sector | Industrials | Health |
52-Week High | $233.31 | $107.71 |
52-Week Low | $161.16 | $79.58 |
Enterprise Value | $29.58B | $25.61B |
Dividend Yield | 1.01% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $210.1, down 0.49% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported strong Q2 2026 results with EPS of $2.74, exceeding expectations, and raised full-year guidance. Recent dividend increases and strategic acquisitions, such as Cloeren, highlight management's confidence in growth. Valuation ratios like P/E of 25.21 and ROE of 14.98% reflect solid profitability, though the stock faces resistance near $212.
The outlook for DOV is positive, driven by robust fundamentals and analyst consensus favoring a buy rating with a $232.33 price target. Risks include market volatility and execution challenges from acquisitions, but diversified end-market exposure and margin expansion support upside potential for investors seeking steady income and growth.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
